GLP-1 RAs and Nonarteritic Anterior Ischemic Optic Neuropathy—Making Sense of the Data

JAMA Ophthalmology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 30, 2025

Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Ophthalmology HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals Network Open Cardiology Dermatology Health Forum Internal Medicine Neurology Oncology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy Accessibility Statement 2025 American Medical Association. All Rights Reserved Search Archive Input Term Sign In Individual inCreate an Account Access through institution Purchase Options: Buy this article Rent Subscribe the journal

Language: Английский

---

Are synthetic incretins associated with ischaemic optic neuropathy?

Eye, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 15, 2025

Language: Английский

---

Semaglutide and non‐arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association

Acta Ophthalmologica, Journal Year: 2025, Volume and Issue: unknown

Published: March 8, 2025

This review covers a seminal study of the relation between exposure to glucagon-like peptide 1 (GLP-1) agonist semaglutide and incident non-arteritic anterior ischaemic optic neuropathy (NAION) in neuro-ophthalmology clinic setting, subsequent studies unselected populations, meta-analysis clinical trials pathophysiology disc retina that may help elucidate NAION patients with diabetes or obesity. In matched cohort patients, those treated using agents other than had rates, orders magnitude higher background population, presumably because referral patterns led enrichment populations at high risk NAION. With semaglutide, rates were 4.28 7.64 times for type 2 (T2D) obesity, respectively, onset was within 14 months treatment initiation, whereas non-semaglutide evenly distributed over 3 years follow-up. Of four health care registry studies, each covering more 100 000 two found relative three without one trend towards being associated only, statistically insignificant imbalances alternatives. The various GLP-1 receptor agonists versus placebo active comparator no significant difference Prior reports long-term glycaemia reduction early worsening retinopathy indicate promote such events proportion its antihyperglycaemic potency. association small, crowded discs, oedema peripapillary exudation suggests semaglutide-related result from changes perfusion lead venous dilation and, presumably, congestion during hypoglycaemia. Given retrospective nature epidemiological causality cannot be inferred, but cautious approach use powerful glycaemia-reducing seems warranted, particularly characteristic can identified by proactive eye examination disc-at-risk characteristics optical coherence tomography.

Language: Английский

---

Semaglutide and Risk of NAION—Additional Insights

JAMA Ophthalmology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 20, 2025

Language: Английский

---

Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association

BMC Ophthalmology, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 14, 2025

Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used worldwide for its cardiometabolic benefits. However, it has recently been associated with nonarteritic anterior ischemic optic neuropathy (NAION). This report presents four clinical cases and explores possible association. Four male patients were diagnosed NAION during semaglutide treatment, treatment durations of less than one year in three cases. All presented significant disc edema intraretinal fluid on optical coherence tomography, along crowded small Bruch's membrane opening diameters (< 1.4 mm cases). One patient exhibited drusen. Visual field defects corresponded ganglion cell layer atrophy tomography. Systemic risk factors varied; two had only obesity. Our observation suggests that individuals diameter may be at developing treatment.

Language: Английский

---

Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?

Obesity Research & Clinical Practice, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

---

Semaglutide and the Retina

Journal of Diabetes, Journal Year: 2025, Volume and Issue: 17(4)

Published: April 1, 2025

Language: Английский

---